South Korea
· Delayed Price · Currency is KRW CJ Bioscience Statistics
Total Valuation
CJ Bioscience has a market cap or net worth of KRW 110.81 billion. The enterprise value is 69.96 billion.
| Market Cap | 110.81B |
| Enterprise Value | 69.96B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CJ Bioscience has 9.11 million shares outstanding. The number of shares has increased by 47.99% in one year.
| Shares Outstanding | 9.11M |
| Shares Change (YoY) | +47.99% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 0.12% |
| Float | 4.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.59 |
| PB Ratio | 1.98 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.31 |
| EV / Sales | 14.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.67 |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.53 |
| Quick Ratio | 3.44 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.34 |
| Interest Coverage | -40.21 |
Financial Efficiency
Return on equity (ROE) is -47.56% and return on invested capital (ROIC) is -30.21%.
| Return on Equity (ROE) | -47.56% |
| Return on Assets (ROA) | -25.83% |
| Return on Capital (ROIC) | -30.21% |
| Revenue Per Employee | 35.76M |
| Profits Per Employee | -154.50M |
| Employee Count | 137 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 19.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.47% |
| 50-Day Moving Average | 12,285.80 |
| 200-Day Moving Average | 13,894.05 |
| Relative Strength Index (RSI) | 51.30 |
| Average Volume (20 Days) | 4,709 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CJ Bioscience had revenue of KRW 4.90 billion and -21.17 billion in losses. Loss per share was -2,433.21.
| Revenue | 4.90B |
| Gross Profit | 1.21B |
| Operating Income | -30.87B |
| Pretax Income | -21.17B |
| Net Income | -21.17B |
| EBITDA | -26.12B |
| EBIT | -30.87B |
| Loss Per Share | -2,433.21 |
Balance Sheet
The company has 49.75 billion in cash and 8.90 billion in debt, giving a net cash position of 40.85 billion or 4,482.73 per share.
| Cash & Cash Equivalents | 49.75B |
| Total Debt | 8.90B |
| Net Cash | 40.85B |
| Net Cash Per Share | 4,482.73 |
| Equity (Book Value) | 56.11B |
| Book Value Per Share | 6,156.95 |
| Working Capital | 37.05B |
Cash Flow
In the last 12 months, operating cash flow was -25.15 billion and capital expenditures -1.07 billion, giving a free cash flow of -26.22 billion.
| Operating Cash Flow | -25.15B |
| Capital Expenditures | -1.07B |
| Free Cash Flow | -26.22B |
| FCF Per Share | -2,877.23 |
Margins
| Gross Margin | 24.75% |
| Operating Margin | -630.16% |
| Pretax Margin | -432.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -535.19% |
Dividends & Yields
CJ Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.99% |
| Shareholder Yield | -47.99% |
| Earnings Yield | -20.01% |
| FCF Yield | -23.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CJ Bioscience has an Altman Z-Score of 1.45. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.45 |
| Piotroski F-Score | n/a |